National Institute on Drug Abuse

National Institute on Drug Abuse. The National Institute on Drug Abuse is a pivotal component of the National Institutes of Health and the leading federal agency supporting scientific research on drug use, addiction, and their health consequences. Established to provide a national evidence base for drug policy and prevention, NIDA's mission encompasses the rapid and effective translation of research into improved public health strategies, treatment protocols, and societal understanding of substance use disorders. Its work informs critical policies at agencies like the Food and Drug Administration and the Substance Abuse and Mental Health Services Administration.

History and mission

The institute was formally established by an act of the United States Congress in 1974, initially operating under the Alcohol, Drug Abuse, and Mental Health Administration. Its creation was driven by growing national concern over drug abuse, exemplified by the earlier Controlled Substances Act of 1970. In 1992, NIDA was integrated into the National Institutes of Health, solidifying its role within the nation's premier biomedical research enterprise. The core mission, as articulated in its strategic plan, is to advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health, a goal that guides collaborations with institutions like the Centers for Disease Control and Prevention and the World Health Organization.

Organizational structure

NIDA is headquartered in Bethesda, Maryland, on the main campus of the National Institutes of Health. The institute is organized into several key divisions and offices that manage its extensive portfolio. These include the Division of Epidemiology, Services and Prevention Research, the Division of Therapeutics and Medical Consequences, and the Intramural Research Program located at the Johns Hopkins Bayview Medical Center in Baltimore. Key operational arms also include the Center for Clinical Trials Network and the Office of Translational Initiatives and Program Innovations, which facilitate partnerships with entities such as the University of California, San Francisco and the Mayo Clinic.

Research focus and programs

The institute's research portfolio is vast, spanning basic neuroscience, clinical trials, epidemiology, and health services research. A primary focus is understanding the neurobiological underpinnings of addiction, often involving advanced imaging studies conducted at facilities like the Brookhaven National Laboratory. NIDA funds and conducts research on the medical consequences of drug use, including HIV/AIDS and hepatitis C, and develops behavioral and pharmacological treatments, such as those for opioid use disorder. Its research also informs prevention strategies implemented in communities and school systems across the United States, evaluating programs in diverse settings from Appalachia to major urban centers like Los Angeles.

Notable initiatives and publications

NIDA launches major public health initiatives and is a primary source of authoritative data on drug use trends. Its flagship publication, *Monitoring the Future*, is an annual survey conducted in partnership with the University of Michigan that tracks substance use among adolescents. The institute also publishes the comprehensive *DrugFacts* series and the *NIDA Notes* research newsletter. Notable campaigns include the National Drug & Alcohol Facts Week and the NIDA International Program, which fosters collaboration with researchers in countries from Colombia to Vietnam. Its research has directly supported public health responses, including guidance during the opioid epidemic.

Leadership and funding

The institute is led by a director appointed by the President of the United States; since 2003, this role has been held by neuroscientist Nora Volkow. Leadership also includes a deputy director and various advisory councils, such as the National Advisory Council on Drug Abuse. NIDA's annual budget is determined by congressional appropriations and often exceeds one billion dollars, funding thousands of research grants, contracts, and training awards to scientists at institutions including the Massachusetts General Hospital, Stanford University, and the Scripps Research Institute. Its funding priorities are closely aligned with public health crises, as seen in its intensified focus on fentanyl and methamphetamine in recent years.

Category:National Institutes of Health Category:United States Public Health Service Category:Organizations based in Maryland Category:Medical and health organizations based in the United States